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Studies of lentivirus infection in ruminants, nonhuman primates, and humans suggest that virus infection of
macrophages plays a central role in the disease process. To investigate whether human immunodeficiency virus
type 1 (HIV-1) can infect chimpanzee macrophages, we recovered monocytes from peripheral blood
mononuclear cells of HIV-1-negative animals and inoculated these and control human monocytes with a panel
of four human-passaged monocytotropic virus strains and one chimpanzee-passaged isolate. HIV-1-infected
human monocytes synthesized proviral DNA, viral mRNA, p24 antigen, and progeny virions. In contrast,
except for the chimpanzee-passaged HIV-1 isolate, chimpanzee monocytes failed to support HIV-1 replication
when cultured under both identical and a variety of other conditions. Proviral DNA was demonstrated only at
background levels in these cell cultures by polymerase chain reaction for gag- and env-related sequences.
Interestingly, the chimpanzee-passaged HIV-1 isolate did not replicate in human monocytes; viral p24 antigens
and progeny virions were not detected. The same monocytotropic panel of HIV-1 strains replicated in both
human and chimpanzee CD4+ T lymphoblasts treated with phytohemagglutinin and interleukind. The failure
of HIV-1 to infect chimpanzee monocytes, which can be overcome by serial in vivo viral passage, occurs
through a block early in the viral life cycle.
Chimpanzees and gibbon apes are the only primates other
than humans susceptible to human immunodeficiency virus
type 1 (HIV-1) infection (2, 7, 12, 14-16, 25). Chimpanzees
are readily infected with as little as four tissue culture
infectious doses (TCID) of virus (3). Following virus inoculation, similarities between viral replication and the immune
response to viral infection in chimpanzees and humans
abound. Virus isolation precedes seroconversion to both
and ~ 2 antigen
4
(Ag)-positive status within 4 to 6
weeks of virus challenge (3, 14-28]. Persistent replication is
evidenced by sequential virus reisolations over periods of
months to years (3, 14) and the emergence of neutralization
escape mutants (30). Despite these observations, all clinical
and laboratory parameters, including total numbers of CD4+
T cells, for all but 1 of more than 100 animals inoculated
worldwide thus far remained within the normal range. However, one research group observed a single animal which
developed transiently depressed CD4+ T cells and platelet
numbers following inoculation with several strains of HIV-1
(13). Proliferative and variable cytotoxic T-cell responses to
HIV-l-specific Ags (7, 37) as well as neutralizing antibody
activities (I4, 29, 30) have
been
in
infected chimpanzees. Each of these host responses is also
found in infected humans.
Studies of lentivirus infection of ruminants, nonhuman
primates, and humans suggest that virus infection of macro-
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phages plays a major role in the disease process (6, 11, 17,
18-20,22-24, 31,35). However, in HIV-1-infected chimpanzees, the identification of monocytes/macrophages as host
cells for virus is lacking. Previously, we demonstrated that
CD4+ T cells from peripheral blood mononuclear cells
(pBMCs) of uninfected donor chimpanzees readily support
low levels of virus replication, induce minimal fusion, and
serve as targets for laboratory strains of virus passaged in
human T-cell lines in the infected host (28). However,
monocytes recovered from HIV-1 IIIB-infected chimpanzees given human T-cell-passaged isolates were virus negative both by cocu~tivationwith human phytohemagglutininand-interleukin-2 (PHmL-2)-stimulated lymphoblasts and by
polymerase chain reaction (PCR) for viral DNA (27, 28).
plasma viremia, central nervous system disease, and
lymphatic hyperplasia all characterize human HIV-1infection but are absent in HIV-1-infected chimpanzees (27, 28).
Both central nervous system and lymph node diseases in
humans are characterized by a productive and persistent
infection of resident macrophages and dendritic cells. Although chimpanzees may develop generalized lymphadenopathy, their lymph nodes show only plasmacytosis, perhaps
secondary to the intravenous administration of large inocula
of virus preparations containing many foreign human cellular
The mechanisms surrounding the differences between
HIV-1 infection of humans and chimpanzees are of potential
importance in understanding disease pathogenesis, in developing effective vaccines, and in developing therapeutic interventions. For example, virus-macrophage interactions for

3854

GENDELMAN E T AL.

binding, penetration, uncoating, or replication in chimpanzee and human cells may differ. To these ends, we studied
the ability of HIV-1 to replicate in its two major target cells
in chimpanzees, monocytes and CD4+ T lymphocytes. To
date, HIV-1 variants that preferentially replicate in human
monocytes have not yet been inoculated in chimpanzees, nor
has there been a formal in vivo demonstration that macrophages from any organ-specific compartment contain virus.
Perhaps, the ability of particular viral strains to productively
infect monocyteslmacrophages is a necessary event for
disease in the chimpanzee.
MATERIALS AND METHODS
Isolation and culture of human and chimpanzee monocytes
and T lymphoblast target cells. Human monocytes were
recovered from PBMCs of HIV-1- and hepatitis B-seronegative donors after leukapheresis and purified by adherence
or by countercurrent centrifugal elutriation of mononuclear
leukocyte-rich fractions of blood cells as previously described (18, 23). Chimpanzee monocytes recovered from
PBMCs of eight HIV-1-seronegative animals were purified
by adherence onto plastic tissue culture dishes. For select
experiments, Ficoll-Hypaque-purified PBMCs were infected
directly with HIV-1 and subsequently purified into either the
T-cell or monocyte fraction by culture techniques outlined
below. Combined adherence and antibody- and complementmediated depletion of T lymphocytes were performed with
OKT3 and rabbit complement. As previous studies describing the isolation and culture of human monocytes demonstrated that supplementation of the medium with specific
cytokines improved long-term culture (6, 23), optimal culture conditions for chimpanzee monocytes were determined.
Monocytes from both species at variable cell concentrations
(0.1 x lo6 to 1.0 x lo6 cells per 24-mm-diameter tissue
culture well) were cultured with or without exogenous cell
growth factors. These included: heat-inactivated A' human
serum, autologous chimpanzee serum, granulocytelmacrophage colony-stimulating factor (GMCSF) (Genzyme, Boston, Mass.), recombinant human macrophage CSF (MCSF)
(a generous gift from Cetus Corp., Emeryville, Calif.), and
conditioned medium from PHAIIL-2-treated chimpanzee
PBMCs. Media tested included Dulbecco modified Eagle
medium (formula 78-176AJ; GIBCO, Grand Island, N.Y.),
RPMI 1640 (GIBCO), and AIM V (GIBCO). Macrophages
were removed after 1 week of culture by gentle scraping with
a rubber policeman in cold phosphate-buffered saline deficient in magnesium and calcium. Total viable cells were
counted by the trypan blue dye exclusion assay. Functional
analysis of the specific cell type was determined by their
ability to phagocytize latex and carboxylate beads. Human
and chimpanzee PBMCs, isolated from whole blood by
Ficoll-diatrizoate density gradient centrifugation, were cultured at lo6 viable cells per ml in RPMI 1640 medium
(GIBCO) with 5 pg of PHA (Sigma Chemical Co., St. Louis,
Mo.) per ml, 10% purified human IL-2 (Advanced Biotechnologies Inc., Columbia, Md.), and 15% heat-inactivated
fetal calf serum (Sterile Systems, Inc., Logan, Utah).
Animals. Housing conditions for the chimpanzees and the
serological assays used to detect HIV-1 antibodies were
previously described (3,4). All animals used as blood donors
for the virus assays were HIV-1 seronegative. The animals
were examined by staff veterinarians every 2 weeks.
HIV-1 infection of monocyte and T-cell targets. PHAlIL-2treated lymphoblasts and monocytes were exposed to HIV-1
at a multiplicity of infection (MOI) of 0.01 infectious virus

per target cell. Four HIV-1 strains originally isolated and
passaged in human primary monocytes (strains ADA, 36,
105, and 24) (18, 23), one strain passaged in T-cell lines
(HIV-1 IIIB), and one chimpanzee serial-passaged isolate
(HIV-lLAVlb)(14, 36) were employed. The TCID was determined by serial dilution of stock virus onto target human
monocytes or lymphoblasts. HIV-1 IIIBlH9 (R. Gallo, contributor) was obtained from the AIDS Research and Reference Reagent Program, AIDS Program, National Institute of
Allergy and Infectious Diseases, and the virus titer on
human and chimpanzee lymphoblasts was determined to be
lo4 50% TCID (TCID,,). HIV-1 IIIB was passaged through
transformed chimpanzee CD4+ cell lines and designated
HIV-1 IIIBICHM-114 (28). PHAIIL-2-treated lymphoblasts
previously cultured for 3 days were infected in medium
supplemented with either 2 pg of Polybrene (Sigma Chemical Co.) or 25 pg of diethylaminoethyl-dextran (Pharmacia,
Piscataway, N.J.) per ml. Monocytes were infected in bulk
PBMCs or cultured as adherent monolayers for 0 to 10 days
prior to use as target cells. Monocytes or PBMCs were
washed twice in complete medium after a 1-h incubation at
37°C with virus. All cultures were refed with fresh medium
every 2 to 3 days at which time culture fluids, cells, andlor
DNA were removed or isolated for viral quantitation and
electron microscopy. Lymphocyte and monocyte cultures
were maintained for 14 to 21 days and 20 to 30 days,
respectively, following infection. Levels of p24 Ag in culture
fluids were determined by enzyme-linked immunosorbent
assays (E. I. Dupont de Nemours & Co., Billerica, Mass.).
For reverse transcriptase (RT) activity, replicate samples of
culture fluids were added to a reaction mixture of Nonidet
P-40 (Sigma), poly(rA). oligo(dT) (Pharmacia), dithiothreitol
(Pharmacia), MgCI,, and [a-"PIdTTP (400 Cilmmol; Amersham Corp., Arlington Heights, Ill.) for 24 h at 37°C. The
mixture was applied to chromatography paper, air dried, and
washed five times in 0.3 M NaCI-0.03 M sodium citrate (pH
7.4) and twice more in 95% ethanol. The paper was dried and
cut, and the radioactivity was counted by liquid scintillation
spectroscopy. HIV-1 IIIB served as the positive control for
both p24 Ag and RT activity assays.
Detection of HIV-1-specific DNA by PCR amplification. All
PCR amplification specimens were coded, and assays were
performed in a blind manner. Cellular lysates of HIV-1infected cells were extracted once each with phenol and then
chloroform-isoamyl alcohol (24:l) prior to ethanol precipitation. PCR amplification of HIV-1 proviral DNA was performed using gag- (SK38139) and env-(SK68169)-specific
primer pairs (1, 9). PCR was performed for 30 cycles, using
an automatic thermal cycler (Perkin-Elmer Cetus, Norwalk,
Conn.) and Taq polymerase (Perkin-Elmer Cetus) as previously described (10). All amplifications used 1 pg of chromosomal DNA as an initial target, and each run was accompanied by a positive-control dilution series and known
negative and reagent controls. In all cases, <20 copies of
HIV-1 proviral DNA were detected. Assessment of specific
amplification was determined by liquid hybridization of the
PCR products with "P-end-labeled oligonucleotide detector
probes SK19 gag and SK70 env (1, 9), followed by gel
electrophoresis (10).
In situ hybridization with HIV-1 RNA probes. Singlestranded HIV-1 ["SIRNA probes were synthesized from a
recombinant DNA plasmid containing SP6lT7 promoters
(Promega Biotec, Madison, Wis.) (21). Cytosmears or adherent cells grown on glass slides treated with silane were fixed
in 4% paraformaldehyde. Specimens were prehybridized in a
solution consisting of 10 mM Tris (pH 7.4), 0.3 M NaCI-0.03
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M sodium citrate (pH 7.4), Denhardt solution [0.02% polyvinylpyrrolidone, 0.02% Ficoll, 0.02% bovine serum albumin), and 200 pg of yeast tRNA per ml at 45°C for 2 h and
hybridized in this solution with 10% dextran sulfate, 5 pM
dithiothreitol, and 35S-labeled HIV-1 RNA (lo6 cpm; Oncor,
Inc., Gaithersburg, Md.). Slides were serially washed in
solutions with RNase to reduce binding of nonhybridized
probe. Autoradiography was performed in absolute darkness
(21).
~ransmissionelectron microscopy. Monocytes or lymphoblast cultures in microtiter plates were fixed in 2% glutaraldehyde in cacodylate buffer and treated with osmium tetroxide (23). The fixed cells were dehydrated, embedded in
Epon, and mounted for sectioning parallel to the culture
surface. Blocks were first thick sectioned and stained with
toluidine blue for light microscopic observations. Those
areas of interest were further thin sectioned, stained with
uranyl acetate, and examined with a Zeiss electron microscope. Approximately 1,000 chimpanzee monocytes from
three different experiments were evaluated for evidence of
cell surface or vacuolar budding of HIV-1 particles.
RESULTS
Maintenance and cultivation of human and chimpanzee
monocytes. Previous studies demonstrated that cell differentiation affects the susceptibility of monocytes to lentiviral
infection (22). In this regard, an evaluation of numerous
culture conditions that could affect monocyte/macrophage
differentiation was performed. Optimal cell viabilities were
obtained at cell concentrations of 7.5 x lo5 cells per ml in
each well of a 24-mm-diameter tissue culture plate. Significant differences between cells cultured in Dulbecco modified
Eagle medium and RPMI 1640 were not demonstrated (data
not shown). In numerous assays, monocytes from humans
and chimpanzees cultured without cytokines and with
MCSF, GMCSF, or combinations of MCSF and GMCSF
yielded 20, 70,70, and 85%, respectively, viable cells after 1
week in culture. Cells maintained in the absence of CSFs
were flattened and pyknotic. Human and chimpanzee monocytes cultured in AIM V demonstrated -75 and 95% cell
viability after 1 week with or without the addition of CSFs.
Morphologically, chimpanzee monocyte cultures demonstrated a heterogeneous appearance, with fusiform cells,
cells with fibroblastlike features, and rounded cells with
diffuse cytoplasm (Fig. 1A and B). Ultrastructurally, monocytes had highly irregular cell surfaces with numerous microvillar lamellipodia and subplasmalemma densities. The
cytoplasm contained numerous mitochondria, bundles of
microfilaments, moderate amounts of rough endoplasmic
reticulum, free ribosomes, and multiple well-developed
Golgi complexes. In addition, numerous phagocytic vacuoles, granules with electron-dense homogeneous contents
(azurophil granules), secondary lysosomes, residual bodies,

FIG. 1. Morphology of cultured chimpanzee monocytes. Chimpanzee PBMCs were purified to >94% monocytes and cultured for
7 days as adherent monolayers in medium with human serum and
GMCSF. All cultures were refed with fresh medium every 2 to 3
days. Studies of the morphology of cultured monocytes demonstrates a heterogeneous monocyte population, with fusiform cells,
cells with fibroblastlike features, and rounded cells with diffuse
cytoplasm. Low-power ( ~ 2 5 0Hoffman
;
modulation) (A) and highpower ( ~ 4 5 0Hoffman
;
modulation) (B) magnifications. Nonspecific
esterase reactivity at day 14 of culture (C) is illustrated.
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FIG. 3. HIV-1 proviral DNA in human and chimpanzee monocytes following virus inoculations. PBMCs purified to >94% and
98% monocytes for chimpanzee and human cells, respectively, were
cultured for 7 days as adherent monolayers in medium with human
serum and infected with isolates ADA (A) or 36 (B) at a MOI of 0.01.
Autoradiographs show samples from HIV-1-infected monocytes
from chimpanzee and human PBMCs cultured for 8 h or 7 or 14
days. (A) Samples from HIV-1 ADA-infected chimpanzee and
human monocytes. Lane 1, Chimpanzee cells with no virus cultured
for 14 days; lanes 5 and 6, 8 h and 14 days, respectively, following
HIV-1 inoculation of chimpanzee monocytes; lanes 2, 3, and 4, 14
days, 7 days, and 8 h, respectively, following HIV-1 inoculation of
human monocytes. The lambda DNA negative (lanes 7 to 9) and
proviral DNA positive controls (lanes 10 to 12) are illustrated. (B)
Samples from HIV-1 36-infected chimpanzee and human monocytes. Lanes 1 and 2, 8 h and 7 days, respectively, following virus
inoculation of chimpanzee monocytes; lanes 3 and 4,7 and 14 days,
respectively, following virus inoculation of human monocytes; lane
5, uninfected human monocytes; lane 6, ADA-infected human
PBMCs; lane 7, HIV proviral DNA positive control.
Days After Infection

FIG. 2. Infection of HIV-1 ADA monocytotropic stock virus
onto human and chimpanzee monocytes. PBMCs purified to >98%
monocytes and cultured for 7 days as adherent monolayers in
medium with human serum and MCSF were exposed in duplicate
determinations to HIV-1 isolate ADA. (A) Human monocytes
infected with 10-fold dilutions of viral inoculum ( 0 , undiluted; +,
1:lO; 0, 1:100; 0, 1:1,000; @, 1:10,000; W, 1:100,000). (B) Viral
replication following the inoculation of human (0)and chimpanzee
(W) monocytes with HIV-1 ADA at a MOI of 0.01. All cultures were
refed with fresh medium every 2 to 3 days, and the culture fluids
were saved at the indicated times and later assayed for p24 Ag and
RT activity.

and lipid inclusions were seen (see Fig. 4). The isolated cells
were nonspecific esterase and granular peroxidase positive
(Fig. 1C). Phagocytosis of latex particles was further demonstrated in the cultured cells after 1week (data not shown).
Chimpanzee monocytes adhering to plastic were 92 to 98%
pure after 1week in culture with o r without complement and
antibody lysis of contaminating T cells. Residual lymphocytes
could be found associated with monocytes for periods of >2
weeks in the absence of exogenous PHA or IL-2 (see Fig. 4).
Minimal levels (52% contaminating cells) were achieved by
complement- and antibody-mediated lysis of the contaminating
cell populations.
Infection of human and chimpanzee monocytes with HIV-1.
The ability of chimpanzee monocytes to support HIV-1
replication was analyzed. Two virus strains with demonstrated tropism for human monocytes (ADA and 36) (18,23)
and one chimpanzee-passaged HIV-1 isolate were used in

initial studies in attempts to infect chimpanzee monocytes.
The titers of the viral stocks in human monocytes were lo5,
lo4, and 0 TCID,, for strains ADA, 36, and HIV-lLAvIb9
respectively. A representative titration of HIV-1 ADA (10fold serial dilutions of virus stock inoculated onto 7-day-old
human monocytes) is illustrated in Fig. 2A. Following infection of human monocytes with ADA (MOI = 0.1), p24 Ag
levels were initially detected in culture fluids at 3 to 5 days,
with maximum levels of 2 5 0 nglml and RT levels in excess
of 60 x lo6 cpmlml. Typical cytopathic effects, including
multinucleated giant cell formation and cell lysis, are seen
beginning by day 7 following infection in the human cells.
Chimpanzee monocytes from four different donors were
inoculated with the three virus strains at an MOI of 0.1 or
0.01. The cells were cultured in media supplemented with
MCSF (1,000 Ulml), GMCSF (100 Ulml), o r MCSF and
GMCSF (1,000 and 100 Ulml, respectively). Monocytes
were inoculated with virus after 7 days of culture. A representative experiment is shown in Fig. 2B. Productive viral
replication could not be demonstrated for either ADA or 36
in any of the four chimpanzee monocyte populations. p24 Ag
and RT activity assays performed on culture supernatants
produced negative results, and there was no evidence of
syncytium formation o r cell death upon microscopic evaluation. The lack of productive virus replication in chimpanzee
monocytes with human-passaged monocytotropic HIV-1
strains was evident regardless of culture conditions (including infection of monocytes directly in the bulk PBMCs),
timing of infection, or the age or sex of the animal donor
(data not shown).
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FIG. 4. Electron microscopic observations of HIV-1-inoculated chimpanzee monocytes. Chimpanzee PBMCs purified to >94% monocytes were cultured 7 days as adherent monolayers in medium with chimpanzee serum and GMCSF and infected with isolate ADA at a MOI
of 0.01 for up to 21 days. Progeny virions were not demonstrated, but contaminating T cells are shown phagocytized by these monocytes.
(A) A 5-day-old culture of a typical macrophage with a irregular lamellipodia surface and eccentric nucleus; adjacent small lymphocytes are
seen. Magnification, ~ 1 3 , 2 0 0 (B)
. A monocyte-associated lymphocyte in a 14-day-old culture. Note the apparent normal ultrastructural
appearance of the lymphocyte. Magnification, ~12,000.(C) A lymphocyte within a cytoplasmic vacuole of a monocyte.
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FIG. 5. HIV-1-specific mRNA in virus-inoculated human and chimpanzee cells. Human and chimpanzee PBMCs purified to 94 and 98%
monocytes, respectively, were cultured for 7 days as adherent monolayers in medium with chimpanzee or human serum and MCSF. Cells
were infected with isolate ADA at a MOI of 0.01 for 14 days. Human PHAIIL-2-stimulatedlymphoblasts infected with ADA for 7 days at a
MOI of 0.01 served as a positive control for this assay. Autoradiography revealed silver grains over HIV-1 mRNA-producing cells.
HIV-1-infected human macrophages (A) and human PBMCs (B) demonstrate abundant HIV-1 mRNA-containing cells following virus
inoculations. Chimpanzee macrophages cultured and infected as the human cells show no measurable HIV-1 mRNA (C).

To analyze the stage of the virus life cycle restricted by the
chimpanzee monocyte, we performed a systematic analysis
of HIV-1 replication following virus infection. PCR amplification for HIV proviral DNA in control HIV-1-infected
human monocytes (ADA o r 36) showed high levels of
amplified products at 7 and 14 days. However, amplification
of DNA extracted from HIV-1-infected chimpanzee monocytes at these time intervals produced barely detectable
signals ( 4 % of human control monocytes) following liquid
hybridization analyses (Fig. 3). The low levels of proviral
DNA seen in HIV-1-inoculated chimpanzee monocyte cultures were typical of that demonstrated in other viral stock
preparations (8). In an attempt to resolve whether the low
levels of HIV-1 DNA were due to input DNA or contaminating lymphocytes in the monocyte preparations, we
treated monocyte cultures with OKT3 and complement prior
to virus infection. Although a reduced PCR signal was
demonstrated, amplification products could still be visualized (data not shown). This suggested that the viral inocula
was a source of the contaminating HIV DNA. Indeed,
analysis by electron microscopy of chimpanzee monocyte
cultures not treated with OKT3 and complement showed
rare but viable T cells in the cell preparations (Fig. 4). No
budding viral particles were ever seen by electron microscopy in these contaminating lymphocytes. This explanation
is further supported by the absence of viral RNA and
progeny virion production in HIV-1-inoculated chimpanzee
monocyte cultures. Of the cells infected with human-passaged HIV-1, 10 and 70% after 7 and 14 days, respectively,
were demonstrated by in situ hybridization to be expressing
HIV-1-specific mRNAs (Fig. 5A). In contrast, no viral
RNAs could be detected in either ADA- or 36-infected
chimpanzee monocytes (Fig. 5C). Production of progeny
HIV-1 particles was evaluated at 7, 14, and 21 days by
transmission electron microscopy. In human cultures, virions were easily identified in intracytoplasmic vacuoles and
via budding from the plasma membrane (Fig. 6). However, a
survey of over 1,000 chimpanzee monocytes in independent

laboratories failed to identify vacuolar o r membrane-associated virus particles at any point following infection. These
results were obtained regardless of whether the chimpanzee
monocytes were prepared for culture immediately following
phlebotomy or 18 h later. Thus, by analyses of proviral
DNA, viral mRNA, p24 viral Ag, RT activity, and ultrastructural virion production, HIV-1 infection was not demonstrated in chimpanzee monocytes with these human-passaged monocytotropic virus strains.
HIV-1 replication in human and chimpanzee PBMCs and
monocytes: a comparison with a panel of viral isolates. To
substantiate the lack of HIV-1 replication with humanpassaged virus in chimpanzee monocytes, virus growth in
lymphoblasts and monocytes from identical donor cells was
examined. Virus from a panel of four monocytotropic strains
and one lvmvhotrovic HIV-1 strain (HIV-1 IIIB) (Table 1)
were inochated at ibentical MOIs onto human and chimpan:
zee monocytes or lymphoblasts. Virus titer, viral mRNA
levels, and maximum levels of released p24 Ag were determined in the virus-inoculated cells. Both human and chimpanzee lymphoblasts supported productive virus replication
when infected with the human- or chimpanzee-passaged
monocytotropic or lymphotropic strain (Table 1). Titers of
each of the virus stock preparations were similar for the
PBMCs of both species and ranged from 10' TCID,, for
isolate 105 to lo4 for ADA. In each instance, the maximum
level of p24 Ag released into culture fluids of infected
lymphoblasts was greater in human cells (60 to 80 ng) than in
chimpanzees (4 and 3 ng) for ADA and HIV-1 IIIB, respectively. The level of p24 Ag correlated with the numbers of
progeny virions observed by electron microscopy (Fig. 7).
Human lymphoblasts underwent ultrastructural degeneration and cytolytic changes following human-passaged HIV-1
infection, and approximately 1 in 10 cells examined demonstrated budding or cell-associated virus particles. Progeny
virions associated with or budding from human-passaged
HIV-1-infected chimpanzee lymphoblasts made up approximately 1 in 100 of total cells examined. No degenerative
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FIG. 6. Electron microscopic observations of HIV-1-infected human monocytes. Human PBMCs were purified to >94 to >98%
monocytes, cultured for 7 days in medium supplemented with MCSF, and infected with ADA at a M01 of 0.01 for 14 days. (A) HIV-1 ADAinfected human monocytes; (B) same monocytes magnified to show extracellular and intravacuolar particles.
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TABLE 1. Viral titers" and levels of p24 Agb in culture fluids of monocytes and lymphoblasts infected with five HIV-1 isolates
Virus isolate

ADA
36
24
105
HIV-1 IIIB
HIV-~LAV~,
"

Human PBMCs

Chimpanzee PBMCs

Titer

~ 2 Ag
4

Titer

~ 2 Ag
4

lo-4
lo-3
lo-3
lo-z
10-4
ND

80
55
50
12
60
ND

lo-'
N D"

5
ND
1
0.4
3
30

10-3

Human monocytes
Titer

lo-4
ND

o
o

Chimpanzee monocytes

~ 2 Ag
4

Titer

~ 2 Ag
4

95
65
60
8

0
0
0
ND
ND
10-3

0
0
0
ND
ND
9

o
o

Titer represents the last dilution positive for viral replication as determined by p24 Ag capture assay.
The p24 Ag levels (in nanograms per milliliter) were measured as describe d in Materials and Methods.
ND, Not done.

changes were seen at an ultrastructural level in chimpanzee
lymphocytes budding human-passaged HIV-1 progeny virions (Fig. 7A and B). Infection with the chimpanzee-passaged
HIV-l,,,,,
isolate, however, resulted in high levels of
viral replication (Table 1). All four human-passaged monocytotropic HIV-1 strains replicated in human monocytes.
The TCID5,s (lo2 to lo5) of these viral strains were similar
in human and chimpanzee PBMCs (Table 1). Productive
viral replication was not demonstrated in chimpanzee monocytes with any of the human-passaged viral strains tested.
However, and in contrast to these previous observations,
HIV-lLAv-lb,the only viral isolate passaged in chimpanzees,
produced easily detectable levels of p24 Ag and progeny
virions in virus-inoculated primary chimpanzee monocytes.
Moreover, virus-induced cytopathicity, multinucleated giant
cells, and cell death were demonstrated in both virusinfected lymphoblasts and monocytes. In lymphoblasts,
significantly higher levels of p24 Ags, compared with those
of the human-propagated strains, were seen in culture fluids
of infected cells. These results taken together clearly demonstrate that serial in vivo virus passage in chimpanzees
results in phenotypic changes of the virus strain. The ability
of this host cell adaptation to produce clinical disease in
chimpanzees awaits further analyses.
DISCUSSION
Chimpanzees and gibbon apes are the only experimental
animal species shown to be infectable with HIV-1(24,7,12,
14-16, 25, 28-30). As the chimpanzee is the closest living
relative of Homo sapiens, the shared permissiveness for
HIV-1 is consistent with a genus- or species-specific relationship usually exhibited by animal lentiviruses. Indeed
intravenous, vaginal, or intracerebral experimental inoculation with either culture supernatants of HIV-1-infected cells
or plasma, brain, or thymic suspensions of AIDS patients
results in a persistent cell-associated viremia in infected
chimpanzees (3, 7, 14, 28, 29). Despite the continuous
reisolation of virus for years, the CD4+ T-cell tropism, and
the development of an HIV-1-specific antibody response,
none of the more than 100 virus-inoculated animals reported
show clinical, hematological, or pathological signs of disease. Except for a single report (14), the absence of plasma
viremia following experimental inoculation with HIV-1 or
virus-containing clinical tissues remains a unique feature of
chimpanzee infections. These observations are in sharp
contrast to the clinical and pathological sequelae observed in
humans and demonstrate important differences between the
interactions of HIV-1 in humans and chimpanzees. These
clinical and pathological differences may correlate with
resistance to HIV-1 infection of chimpanzee monocytes in

vivo or with limited involvement of the reticuloendothelial
cell system.
This examination of the human-passaged HIV-1-infected
chimpanzee monocyte demonstrates restriction of infection
at an early stage in the virus life cycle. However, these
analyses do not preclude the possibility of in vivo infection,
as isolated monocytes from blood behave biologically and
functionally differently than tissue macrophages. However,
as multiple culture conditions were utilized in attempts to
optimize in vitro infection without success, it appears that in
vitro susceptibilities between chimpanzee and human monocytes for HIV-1 of human passage are distinct. Only low
levels of proviral DNA were detected in the absence of
virus-specific mRNA. This suggests that the block may be
mediated early, at the level of receptor-virus interaction(s)
or cell-to-cell transmission. Indeed, the CD4 molecule, the
receptor for HIV-1 in virus-susceptible human cells, is
molecularly and biologically distinct in the chimpanzee (5).
HIV-1 envelope proteins allow syncytium formation between cells expressing human but not chimpanzee CD4.
DNA sequence analysis of regions of the CD4 gene which
govern cell fusion show amino acid heterogeneity between
the two species; chimpanzee CD4+ cells bearing human
amino acid residue 87 support syncytium formation, while
human CD4 cells bearing chimpanzee residue 87 do not.
Furthermore, infection of human cells expressing the chimpanzee CD4 gene is insensitive to lysosomotropic agents,
implying that viral penetration does not require endocytosis
as was previously demonstrated with human CD4-expressing cells. The binding affinity of virus to chimpanzee CD4,
however, remains equivalent to that of human CD4' T cells
(5, 28). These subtle differences between human and chimpanzee CD4 receptors may well be associated with both
resistance to virus-induced cytopathicity and the characteristic low-level virus released from infected lymphocytes (28).
Perhaps a low level of CD4 expression in an altered configuration plays a role in the resistance of the chimpanzee
monocyte to virus infection. This could explain the permissiveness of the chimpanzee-passaged HIV-l,Avlb isolate.
Alternatively, cytokines produced from HIV-1-inoculated
chimpanzee lymphocytes and monocytes could effect susceptibility to HIV-1 infection. Indeed, recent reports demonstrate that when 2 5 U of alpha interferon per ml is added
to cultures of human monocytes, HIV-1 infection is abrogated. This block in HIV-1 infection is localized at the level
of proviral DNA (19, 20).
Macrophages play essential roles in the virus-specific
immune response in the host by presenting Ag to lymphocytes during infection and by serving as accessory cells to
lymphocytes (32). Further indirect evidence of the in vivo
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FIG. 7. Comparative electron micrographs of HIV-1-infected
chimpanzee and human PHAIIL-Zstimulated PBMCs. Human and
chimpanzee PBMCs previously cultured for 3 days in medium with
PHA and IL-2 were exposed to HIV-1 ADA at a MOI of 0.01. (A and
B) Focal budding of HIV-1 particles from the surface of a chimpanzee lymphocyte. Note the thickened celVvirus-associated membranes involved in virus budding in panel B. (C) Cytolytic response
of human PBMCs to HIV-1. Note the large numbers of virus
particles associated with cellular debris. Magnification, ~96,000.

resistance of these cells in chimpanzees comes on the
realization that after experimental inoculation of large
amounts of virus or virus-producing cells into animals, a full
range of virus-specific immunity develops (7) without detectable infection in macrophages (27, 28). This immunity requires efficient Ag processing of the virus-infected cells in
mononuclear phagocytes, leading to an abortive infection,
and thus further supports the findings presented here. Macrophages also have protective functions through their abilities to ingest and kill invading microorganisms and therefore
provide an important element for host defense against disease (32). Paradoxically these same cells are targets for a
number of microbial pathogens including HIV-1. It is of
particular interest that the target tissues in which large
numbers of HIV-1-infected macrophages reside constitute
the identical tissues involved in disease (31). In humans, the
lung, brain, and spinal cord are all primary sites of replication for HIV-1 in the macrophage and all demonstrate
significant and persistent levels of viral replication which
correlate with histopathological alterations and clinical disease (24). HIV-1-related interstitial pneumonitis, subacute
encephalopathy, and spinal cord myelopathy are features
associated with HIV-1 infection of macrophages (24). Furthermore, the numbers of infected cells correlate with the
observed histopathology in many cases. Not all tissue macrophages are equally permissive for lentiviral infections. For
example, in horses infected with equine infectious anemia
virus, Kupffer cells present in the liver have been demonstrated to be a major site of virus replication (33). In
HIV-1-infected humans we studied, liver or Kupffer cell
infection and associated pathology is less frequent (26, 34).
In a 8-month-old chimpanzee chronically infected with
HIV-1 IIIB, liver infection was not demonstrated (27). We
previously demonstrated that monocytes cultured from peripheral blood of HIV-l IIB-infected chimpanzees did not
contain HIV-specific gene products or release progeny virions (27, 28). The lack of susceptibility of liver, connective
tissue, bone, and kidney tissues to pathological processes
may be traced to the lack of permissiveness of their respective tissue macrophages in supporting productive HIV-1
infection.
The lack of apparent HIV-1 infection in chimpanzee
monocytes coupled with the previously reported continuous
but noncytopathic infection of lymphocytes demonstrate
two aspects of controlled virus replication in the host and
further defines the animal models' application to AIDS
research. Further investigations into the unique aspects of
these virus-host cell interactions should further elucidate the
necessary mechanisms that correlate with and precipitate
disease in humans. This will likely require the use of an
HIV-1 isolate or strain which efficiently infects chimpanzee
macrophages in vivo. Indeed, one such virus strain was
found. Ultimately, understanding the mechanisms of virus
adaptation to its natural host cells should provide insights
into the pathogenesis of HIV-1 in its human host.
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